摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-fluoro-3-[1-(trans-1-methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]-2-oxo-2,3-dihydro-1,3-benzoxazole-5-carbonitrile hydrochloride | 1134196-79-4

中文名称
——
中文别名
——
英文名称
7-fluoro-3-[1-(trans-1-methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]-2-oxo-2,3-dihydro-1,3-benzoxazole-5-carbonitrile hydrochloride
英文别名
——
7-fluoro-3-[1-(trans-1-methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]-2-oxo-2,3-dihydro-1,3-benzoxazole-5-carbonitrile hydrochloride化学式
CAS
1134196-79-4
化学式
C23H30FN3O4*ClH
mdl
——
分子量
467.968
InChiKey
LVDXTWPHQGXJHY-OPYRIQLESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.03
  • 重原子数:
    32.0
  • 可旋转键数:
    6.0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.65
  • 拓扑面积:
    80.63
  • 氢给体数:
    0.0
  • 氢受体数:
    7.0

文献信息

  • [EN] COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE<br/>[FR] COMPOSÉS PRÉSENTANT UNE ACTIVITÉ AU NIVEAU DU RÉCEPTEUR M1 ET LEURS UTILISATIONS EN MÉDECINE
    申请人:GLAXO GROUP LTD
    公开号:WO2009037294A1
    公开(公告)日:2009-03-26
    Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.
    提供具有公式(I)或其盐的化合物:其中R4、R5、R6、Q、A、Y和R按描述定义。披露了这些化合物作为药物的使用和在制造用于治疗精神病性障碍、认知障碍和阿尔茨海默病药物中的应用。本发明还公开了包含这些化合物的药物组合物。
  • Compounds which have activity at M1 receptor and their uses in medicine
    申请人:Cooper David Gwyn
    公开号:US20100204272A1
    公开(公告)日:2010-08-12
    Compounds of formula (I) or a salt thereof are provided: wherein R 4 , R 5 , R 6 , Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.
    本发明提供了化学式(I)的化合物或其盐:其中R4,R5,R6,Q,A,Y和R的定义如说明书中所定义。本发明还揭示了将该化合物用作药物以及制造用于治疗精神障碍,认知障碍和阿尔茨海默病的药物的用途。本发明还揭示了包含该化合物的制药组合物。
  • Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine
    申请人:Cooper David Gwyn
    公开号:US20120316196A1
    公开(公告)日:2012-12-13
    Compounds of formula (I) or a salt thereof are provided: wherein R 4 , R 5 , R 6 , Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.
    提供化学式(I)的化合物或其盐: 其中R4、R5、R6、Q、A、Y和R的定义如说明书所述。本发明还公开了将该化合物用作药物治疗精神疾病、认知障碍和阿尔茨海默病以及制造药物的用途。本发明还公开了包含该化合物的制药组合物。
  • COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE
    申请人:Glaxo Group Limited
    公开号:EP2194982A1
    公开(公告)日:2010-06-16
  • US8278328B2
    申请人:——
    公开号:US8278328B2
    公开(公告)日:2012-10-02
查看更多